The whirling dervish of Regmed - Q4 and FY12 results
The Bottom Line: ACTC – the “whirling dervish” of companies – has announced promising data from its most advanced clinical programs in AMD and SMD and made solid progress in clinical trials. However, losses continue to increase … reported a Q4/12 loss from operations of $6.2 M compared to a loss from operations of $5.8 M in the Q4/11. For FY12, ACTC reported a loss from operations of $21.1 M compared to a loss of $21.1 M a year before. At least the Q4/12 net loss decreased incrementally . Also, the net loss decreased year to year of $28.5 M versus $72.8 M. Love the ego driven CEO conference call comments … “I used to not answer my phone because it was always somebody we owed money to. Now I don’t answer it because it’s always somebody who wants to invest in the company”. With issued – 2.232 B and outstanding shares of 1.743 B and an $8.496 B shareholder deficit and total liabilities– no wonder Rabin won’t take investors calls. Can anyone take responsibility to make ACTC a real company – that has good science, growing and even glowing trial results! ACTC closed at $0.07 on 3/7/13 – moving from $0.08 since 2/20/13 and $0.09 on 1/29/13.